30 closest matches · ranked by relevance
Neoplasms, Prostate · Prostate Cancer After a Radical Treatment
Primary: Time to Prostate-specific Antigen (PSA) Doubling From Baseline (in Days) — 365.5; 458.0; NA; NA days — p=<0.001
Cancer
Primary: PedsQL 3.0 Cancer Module Scale — 71.59 score on a scale
Acute Myocardial Infarction
Primary: Acute Phase Response (CRP Levels) — 60.03; 86.35; 213.75 mg x day/L (milligram x day/liter)
HIV
Primary: Cumulative Incidence of ART Initiation 14 Days After Clinical Eligibility in Treatment Eligible HIV-infected Patients — 2585; 3753 participants
Acute Promyelocytic Leukemia
Primary: Complete Response (CR) Rate — 55; 5; 15 Participants
HIV-1 Infection · Cognitive Impairment
Primary: Change in Global Cognitive Functioning — 0.08; 0.31; 0.25 score on a scale
Wound of Skin
Primary: Change of Pain on Harvesting of Skin at Donor Site. — 2.6 millimeters
HIV · Inflammation · Atherosclerosis
Primary: Change in Arterial FDG Uptake (From Baseline) in the Most Diseased Segment — -0.126; 0.026 TBR
Veteran · Smoking Cessation
Primary: Number of Participants With Abstinence or Non-Abstinence at 6-month Follow-up — 38; 40; 77; 83 Participants
Stroke
Primary: Neurological Condition of the Patient — 23; 52; 60; 29 patients
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Cost Sharing, Acute Coronary Syndrome
Primary: Kaplan-Meier Cumulative Incidence Rate of Major Adverse Cardiovascular Events — 10.17; 10.93 Percentage of Participants — p=0.3503
Aortic Insufficiency
Primary: Primary Safety Outcome Measure: Survival Defined as Survival Free From All Cause Death at 6 Months Postprocedure. — 100 percentage of participants
Lower Respiratory Tract Infection (LRTI)
Primary: Total Antibiotic Exposure Days — 4.2; 4.3 days — p=0.87
Risk Reduction
Primary: Proportion of Participants in Each Arm Achieving Viral Suppression to <50 Copies/ml — 59; 48 Participants
Smoking Cessation
Primary: Number of Participants Who Stopped Smoking by 12 Month Post Treatment — 31; 41 participants
Harm Reduction · HIV Infections · Drug Use
Primary: Percentage of Participants With HIV Viral Load Suppression — 11 Participants
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
Sedentary Lifestyle
Primary: Change in Time Spent Sitting or Lying Down at 6 Months — -40.36; -8.51 Minutes — p=0.003
Aortic Insufficiency
Primary: Primary Safety Outcome Measure: Survival Defined as Survival Free From All Cause Death at 6 Months Postprocedure — 100 percentage of participants
Malignancy · Metastasis · Hemoptysis
Primary: Feasibility of Same-session MRI-only Simulation as Defined as More Than 70% of Patients Receiving at Least 70% of Their Scheduled Treatment Fractions on the First…
HIV Infections
Primary: The Primary Outcome of This Study is the Proportion of Patients Having Detectable HIV-1 RNA Using the Single Copy Assay After 48 Weeks of Treatment and the Study…
Rheumatoid Arthritis
Primary: Phase I: Number of Participants With Demographic Characteristics in Monotherapy and Combination Therapy — 79; 75; 73; 77 Participants
Depressive Symptoms · HIV Infections
Primary: Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a — 17.8; 19.2; 19.7; 17.7 Units on a scale
Cerebral Hemorrhage · Brain Hemorrhage · Cerebral Parenchymal Hemorrhage
Primary: Global Disability (Functional Outcome) Assessed Via the Ordinal Modified Rankin Score (mRS) — 32; 20; 4; 2 Participants
Vascular Disease
Primary: Immediate Sealing Evidenced by no Bleeding on Clamp Release. — 65; 101 Treatment sites — p=0.05
Malaria
Primary: Cure Rate on Day 28 — 197; 603 Participants — p=>0.05
HIV-1 Infection · Kaposi's Sarcoma
Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911
Liver Fibrosis · Liver Inflammation
Primary: ARFI/VTQ and ARFI/VTIQ Liver Shear Wave Speed vs. Liver Histologic Fibrosis Score — 1.69; 2.01 m/s — p=<0.0001
Hemorrhage, Surgical · Blood Loss, Surgical · Blood Loss, Postoperative
Primary: Incidence of Perioperative (Periop) Bleeding, Primary Effectiveness Composite Endpoint, Modified Intent to Treat (mITT) Population — 2103; 2244 number of wins — p=0.748